Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry
U. Nitz, M. Graeser, O. Gluz, S. Kümmel, M. Just, C. Jackisch, C. zu Eulenburg, M. Christgen, N. Harbeck, West German Study Group · 2025
Read Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry by U. Nitz, M. Graeser, O. Gluz, S. Kümmel, M. Just, C. Jackisch, C. zu Eulenburg, M. Christgen, N. Harbeck, West German Study Group (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12702365.txt.
Description
Nitz and co-authors reported ten-year outcomes from a breast cancer registry in two thousand twenty-five. The original trial screened patients with a gene test. Low-risk scores spared some women chemotherapy entirely. Others were randomized between two chemo recipes. The registry then followed everyone long-term. Hormone-positive early cancers filled the cohort.
Survival at ten years is the headline measure. Gene-guided selection held up over the decade. Chemo arms can be compared on mature data. Endocrine-only patients validate the sparing strategy. Such registries prove trial ideas in real practice. Oncologists counsel with firmer numbers now. De-escalation gains its long safety evidence.
Catalog record
| CREATOR | U. Nitz, M. Graeser, O. Gluz, S. Kümmel, M. Just, C. Jackisch, C. zu Eulenburg, M. Christgen, N. Harbeck, West German Study Group |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |